Compiled from ASCO 2012 abstracts: Lymphoma | CLL
See also ASCO 2012 follicular lymphoma abstracts
1. A subgroup analysis of small lymphocytic and marginal zone lymphomas in the Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden indolent non-Hodgkin lymphoma. |
2. Survival with splenectomy in splenic marginal zone lymphoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. | 2012 ASCO Annual Meeting Abstracts
3. Survival outcomes in marginal zone lymphomas in the rituximab era: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database.
4. Ocular adnexal lymphoma (OAL)-outcomes for 82 patients (pts) treated at a single center. |
5. Prevalence of autoimmune conditions in patients with marginal zone lymphoma: Exploratory analysis of a series of consecutive patients.
6. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).
7. Brentuximab vedotin for relapsed or refractory non-Hodgkin lymphoma: Preliminary results from a phase II study.
8. LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL.
9. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL).
10. Geographic variation of extranodal sites of mucosal associated lymphoid tissue lymphoma (MALToma): Analysis of series from two institutions. | 2012 ASCO Annual Meeting Abstracts
11. LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL.
|